691 related articles for article (PubMed ID: 28216244)
1. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial.
Sissoko MS; Healy SA; Katile A; Omaswa F; Zaidi I; Gabriel EE; Kamate B; Samake Y; Guindo MA; Dolo A; Niangaly A; Niaré K; Zeguime A; Sissoko K; Diallo H; Thera I; Ding K; Fay MP; O'Connell EM; Nutman TB; Wong-Madden S; Murshedkar T; Ruben AJ; Li M; Abebe Y; Manoj A; Gunasekera A; Chakravarty S; Sim BKL; Billingsley PF; James ER; Walther M; Richie TL; Hoffman SL; Doumbo O; Duffy PE
Lancet Infect Dis; 2017 May; 17(5):498-509. PubMed ID: 28216244
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.
Sissoko MS; Healy SA; Katile A; Zaidi I; Hu Z; Kamate B; Samake Y; Sissoko K; Mwakingwe-Omari A; Lane J; Imeru A; Mohan R; Thera I; Guindo CO; Dolo A; Niare K; Koïta F; Niangaly A; Rausch KM; Zeguime A; Guindo MA; Bah A; Abebe Y; James ER; Manoj A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Doumbo O; Duffy PE
Lancet Infect Dis; 2022 Mar; 22(3):377-389. PubMed ID: 34801112
[TBL] [Abstract][Full Text] [Related]
3. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial.
Koita OA; Sangaré L; Miller HD; Sissako A; Coulibaly M; Thompson TA; Fongoro S; Diarra Y; Ba M; Maiga A; Diallo B; Mushatt DM; Mather FJ; Shaffer JG; Anwar AH; Krogstad DJ
Lancet Infect Dis; 2017 Dec; 17(12):1266-1275. PubMed ID: 28916443
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
Sagara I; Healy SA; Assadou MH; Gabriel EE; Kone M; Sissoko K; Tembine I; Guindo MA; Doucoure M; Niaré K; Dolo A; Rausch KM; Narum DL; Jones DL; MacDonald NJ; Zhu D; Mohan R; Muratova O; Baber I; Coulibaly MB; Fay MP; Anderson C; Wu Y; Traore SF; Doumbo OK; Duffy PE
Lancet Infect Dis; 2018 Sep; 18(9):969-982. PubMed ID: 30061051
[TBL] [Abstract][Full Text] [Related]
5. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial.
Coulibaly D; Kone AK; Traore K; Niangaly A; Kouriba B; Arama C; Zeguime A; Dolo A; Lyke KE; Plowe CV; Abebe Y; Potter GE; Kennedy JK; Galbiati SM; Nomicos E; Deye GA; Richie TL; James ER; Kc N; Sim BKL; Hoffman SL; Doumbo OK; Thera MA; Laurens MB;
EClinicalMedicine; 2022 Oct; 52():101579. PubMed ID: 35928033
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial.
Tshefu AK; Gaye O; Kayentao K; Thompson R; Bhatt KM; Sesay SS; Bustos DG; Tjitra E; Bedu-Addo G; Borghini-Fuhrer I; Duparc S; Shin CS; Fleckenstein L;
Lancet; 2010 Apr; 375(9724):1457-67. PubMed ID: 20417857
[TBL] [Abstract][Full Text] [Related]
7. Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
Tripura R; von Seidlein L; Sovannaroth S; Peto TJ; Callery JJ; Sokha M; Ean M; Heng C; Conradis-Jansen F; Madmanee W; Peerawaranun P; Waithira N; Khonputsa P; Jongdeepaisal M; Pongsoipetch K; Chotthanawathit P; Soviet U; Pell C; Duanguppama J; Rekol H; Tarning J; Imwong M; Mukaka M; White NJ; Dondorp AM; Maude RJ
Lancet Infect Dis; 2023 Jan; 23(1):81-90. PubMed ID: 36174595
[TBL] [Abstract][Full Text] [Related]
8. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
[TBL] [Abstract][Full Text] [Related]
9. Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.
Ogutu B; Yeka A; Kusemererwa S; Thompson R; Tinto H; Toure AO; Uthaisin C; Verma A; Kibuuka A; Lingani M; Lourenço C; Mombo-Ngoma G; Nduba V; N'Guessan TL; Nassa GJW; Nyantaro M; Tina LO; Singh PK; El Gaaloul M; Marrast AC; Chikoto H; Csermak K; Demin I; Mehta D; Pathan R; Risterucci C; Su G; Winnips C; Kaguthi G; Fofana B; Grobusch MP
Lancet Infect Dis; 2023 Sep; 23(9):1051-1061. PubMed ID: 37327809
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya.
Steinhardt LC; Richie TL; Yego R; Akach D; Hamel MJ; Gutman JR; Wiegand RE; Nzuu EL; Dungani A; Kc N; Murshedkar T; Church LWP; Sim BKL; Billingsley PF; James ER; Abebe Y; Kariuki S; Samuels AM; Otieno K; Sang T; Kachur SP; Styers D; Schlessman K; Abarbanell G; Hoffman SL; Seder RA; Oneko M
Clin Infect Dis; 2020 Aug; 71(4):1063-1071. PubMed ID: 31555824
[TBL] [Abstract][Full Text] [Related]
12. Safety and Differential Antibody and T-Cell Responses to the
Jongo SA; Church LWP; Mtoro AT; Chakravarty S; Ruben AJ; Swanson PA; Kassim KR; Mpina M; Tumbo AM; Milando FA; Qassim M; Juma OA; Bakari BM; Simon B; James ER; Abebe Y; Kc N; Saverino E; Gondwe L; Studer F; Fink M; Cosi G; El-Khorazaty J; Styers D; Seder RA; Schindler T; Billingsley PF; Daubenberger C; Sim BKL; Tanner M; Richie TL; Abdulla S; Hoffman SL
Am J Trop Med Hyg; 2019 Jun; 100(6):1433-1444. PubMed ID: 30994090
[TBL] [Abstract][Full Text] [Related]
13. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
van der Plas JL; Kuiper VP; Bagchus WM; Bödding M; Yalkinoglu Ö; Tappert A; Seitzinger A; Spangenberg T; Bezuidenhout D; Wilkins J; Oeuvray C; Dhingra SK; Thathy V; Fidock DA; Smidt LCA; Roozen GVT; Koopman JPR; Lamers OAC; Sijtsma J; van Schuijlenburg R; Wessels E; Meij P; Kamerling IMC; Roestenberg M; Khandelwal A
Lancet Infect Dis; 2023 Oct; 23(10):1164-1174. PubMed ID: 37414066
[TBL] [Abstract][Full Text] [Related]
14. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
Oneko M; Steinhardt LC; Yego R; Wiegand RE; Swanson PA; Kc N; Akach D; Sang T; Gutman JR; Nzuu EL; Dungani A; Kim Lee Sim B; Oloo PN; Otieno K; Bii DK; Billingsley PF; James ER; Kariuki S; Samuels AM; Jongo S; Chebore W; Abdulla S; Daubenberger C; Mpina M; Styers D; Potter GE; Abarbanell G; Richie TL; Hoffman SL; Seder RA
Nat Med; 2021 Sep; 27(9):1636-1645. PubMed ID: 34518679
[TBL] [Abstract][Full Text] [Related]
15. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.
Eziefula AC; Bousema T; Yeung S; Kamya M; Owaraganise A; Gabagaya G; Bradley J; Grignard L; Lanke KH; Wanzira H; Mpimbaza A; Nsobya S; White NJ; Webb EL; Staedke SG; Drakeley C
Lancet Infect Dis; 2014 Feb; 14(2):130-9. PubMed ID: 24239324
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial.
Abdulla S; Sagara I; Borrmann S; D'Alessandro U; González R; Hamel M; Ogutu B; Mårtensson A; Lyimo J; Maiga H; Sasi P; Nahum A; Bassat Q; Juma E; Otieno L; Björkman A; Beck HP; Andriano K; Cousin M; Lefèvre G; Ubben D; Premji Z
Lancet; 2008 Nov; 372(9652):1819-27. PubMed ID: 18926569
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Sagara I; Diallo A; Kone M; Coulibaly M; Diawara SI; Guindo O; Maiga H; Niambele MB; Sissoko M; Dicko A; Djimde A; Doumbo OK
Am J Trop Med Hyg; 2008 Nov; 79(5):655-61. PubMed ID: 18981499
[TBL] [Abstract][Full Text] [Related]
18. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of
Jongo SA; Shekalaghe SA; Church LWP; Ruben AJ; Schindler T; Zenklusen I; Rutishauser T; Rothen J; Tumbo A; Mkindi C; Mpina M; Mtoro AT; Ishizuka AS; Kassim KR; Milando FA; Qassim M; Juma OA; Mwakasungula S; Simon B; James ER; Abebe Y; Kc N; Chakravarty S; Saverino E; Bakari BM; Billingsley PF; Seder RA; Daubenberger C; Sim BKL; Richie TL; Tanner M; Abdulla S; Hoffman SL
Am J Trop Med Hyg; 2018 Aug; 99(2):338-349. PubMed ID: 29943719
[TBL] [Abstract][Full Text] [Related]
19. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.
Dicko A; Brown JM; Diawara H; Baber I; Mahamar A; Soumare HM; Sanogo K; Koita F; Keita S; Traore SF; Chen I; Poirot E; Hwang J; McCulloch C; Lanke K; Pett H; Niemi M; Nosten F; Bousema T; Gosling R
Lancet Infect Dis; 2016 Jun; 16(6):674-684. PubMed ID: 26906747
[TBL] [Abstract][Full Text] [Related]
20. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
Murphy SC; Deye GA; Sim BKL; Galbiati S; Kennedy JK; Cohen KW; Chakravarty S; Kc N; Abebe Y; James ER; Kublin JG; Hoffman SL; Richie TL; Jackson LA
PLoS Pathog; 2021 May; 17(5):e1009594. PubMed ID: 34048504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
